News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major market-moving news in the past hour; trading appeared range-bound.
  • No significant economic data releases were reported in the last hour.
  • Equity futures and indexes showed little net movement amid the lack of headlines.
  • No central bank comments or policy actions were announced in the past hour.
  • No new geopolitical incidents or escalations were reported in the last hour.
  • No notable political developments or legislative actions emerged in the past hour.

Latest Articles

Roundtable Secures Enterprise Technology Platform Partnership with Mario Nawfal, the World’s #1 Most-Viewed Journalist

Roundtable Secures Enterprise Technology Platform Partnership with Mario Nawfal, the World’s #1 Most-Viewed Journalist

Roundtable (NASDAQ: RTB), an AI-powered and DeFi-enabled enterprise media platform, announced a comprehensive technology partnership with Mario Nawfal, the world's most-viewed journalist. Under this agreement, Roundtable will provide publishing, monetization, syndication, and business operation infrastructure for Nawfal's owned digital platform, ma…

ImmunityBio: Buy the Commercial Momentum Behind ANKTIVA Ahead of PDUFA

ImmunityBio: Buy the Commercial Momentum Behind ANKTIVA Ahead of PDUFA

ImmunityBio (IBRX) is a buy here. The market is discounting ANKTIVA's commercial momentum after an overreaction to promotional conduct headlines earlier this year. With an accepted sBLA, compelling QUILT efficacy numbers, and a PDUFA date of 01/06/2027, the path to re-rating is clear — but not risk-free. Trade plan: enter $7.70, stop $6.50, target …

CO2 Energy Transition Corp. (Nasdaq: NOEM) Signs Letter of Intent with Texas-Based Energy Company to Advance Domestic Lithium Recovery and Strontium Ferrite Production for Defense Applications

CO2 Energy Transition Corp. (Nasdaq: NOEM) Signs Letter of Intent with Texas-Based Energy Company to Advance Domestic Lithium Recovery and Strontium Ferrite Production for Defense Applications

CO2 Energy Transition Corp. (Nasdaq: NOEM), a special purpose acquisition company focused on energy transition, announced a non-binding Letter of Intent with a Texas-based oil and gas company to recover lithium and strontium from subsurface brines. This strategy seeks to leverage existing oilfield infrastructure to support domestic critical mineral…

Homeland Security Asks Four States to Reexamine Voter Rolls for Non-Citizens

Homeland Security Asks Four States to Reexamine Voter Rolls for Non-Citizens

Homeland Security Secretary Markwayne Mullin has asked secretaries of state in California, New Jersey, Nevada and Pennsylvania to examine their voter registration lists for possible non-citizen registrants. The request, delivered in letters that cite preliminary reviews of state records, follows a presidential address on election security. The Depa…

Buying the Oral Wegovy Recovery: A Measured Long on Novo Nordisk

Buying the Oral Wegovy Recovery: A Measured Long on Novo Nordisk

Novo Nordisk has moved from broken market leadership to a credible comeback thanks to a successful oral Wegovy pill launch and improving technicals. At a $225.8B market cap and roughly 12x P/E, the stock looks like a recovery trade rather than a growth premium. This idea lays out an actionable long: entry at $50.59, stop at $45.00, target $68.00 ov…

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Compass Therapeutics announced that data from its randomized Phase 2/3 COMPANION-002 trial evaluating tovecimig combined with paclitaxel in patients with advanced biliary tract cancer will be presented orally at the upcoming ESMO Congress. This presentation highlights clinical progress in their bispecific antibody program targeting DLL4 and VEGF-A …

Why I'm Turning Bullish on Moelis & Company After the Recent Pullback

Why I'm Turning Bullish on Moelis & Company After the Recent Pullback

Moelis & Company (MC) just gave investors a clean entry after a sharp sell-off. The advisory firm still prints high ROE, solid free cash flow and a dividend yield that cushions downside. Technical momentum and falling short interest add to the bull case. Here's a pragmatic trade plan with entry, stop and targets across three horizons.

Why I’m Aggressively Long monday.com After the Melt‑Down

Why I’m Aggressively Long monday.com After the Melt‑Down

monday.com plunged through 2026 amid AI-driven fear and headline selling. The business continues to grow 24% YoY, just reported $351M in revenue and positive operating cash flow, and now trades at a fraction of prior multiples. I’m putting a clear trade on: long MNDY at current levels with a $140 target and $69 stop — a high-conviction, high-risk a…

Huadi International Group Co., Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Huadi International Group Co., Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Huadi International Group Co., Ltd. announced it received a Nasdaq notification regarding non-compliance with the minimum $1.00 bid price requirement. The company has a 180-day period until January 11, 2027, to regain compliance, with a potential additional 180-day extension if certain conditions are met, including possibly implementing a reverse s…